<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.0//EN" "http://www.ncbi.nlm.nih.gov:80/entrez/query/static/PubMed.dtd">
<ArticleSet>
	<Article>
		<Journal>
			<PublisherName/>
			<JournalTitle>IJOTM</JournalTitle>
			<Issn>2008-6490</Issn>
			<Volume>5</Volume>
			<Issue>2</Issue>
			<PubDate PubStatus="epublish">
				<Year>2014</Year>
				<Month>05</Month>
				<Day>04</Day>
			</PubDate>
		</Journal>
		<ArticleTitle>Management of Heparin-Induced Thrombocytopenia with Fondaparinux in a Patient with Left Ventricular Assist Device</ArticleTitle>
		<FirstPage>83</FirstPage>
		<LastPage>86</LastPage>
		<Language>EN</Language>
		<AuthorList>
			<Author>
				<FirstName>V</FirstName>
				<LastName>Velagic</LastName>
			</Author>
			<Author>
				<FirstName>J</FirstName>
				<LastName>Samardzic</LastName>
				<Affiliation>University of Zagreb School of Medicine, Zagreb, Croatia. jure.samardzic@gmail.com</Affiliation>
			</Author>
			<Author>
				<FirstName>Z</FirstName>
				<LastName>Baricevic</LastName>
			</Author>
			<Author>
				<FirstName>B</FirstName>
				<LastName>Skoric</LastName>
			</Author>
			<Author>
				<FirstName>M</FirstName>
				<LastName>Cikes</LastName>
			</Author>
			<Author>
				<FirstName>H</FirstName>
				<LastName>Gasparovic</LastName>
			</Author>
			<Author>
				<FirstName>B</FirstName>
				<LastName>Biocina</LastName>
			</Author>
			<Author>
				<FirstName>D</FirstName>
				<LastName>Milicic</LastName>
			</Author>
		</AuthorList>
		<History>
			<PubDate PubStatus="received">
				<Year>2013</Year>
				<Month>11</Month>
				<Day>30</Day>
			</PubDate>
		</History>
		<Abstract>Heparin-induced thrombocytopenia is an immune-mediated serious adverse effect of heparin therapy. It is a relatively frequent complication among patients with mechanical circulatory support. Herein, we present a patient with severe heart failure and sepsis who developed heparin- induced thrombocytopenia shortly after implantation of left ventricular assist device as a bridge to transplantation and who was successfully treated with fondaparinux.</Abstract>
	</Article>
</ArticleSet>
